Dear All, OHAMR (European Partnership on One Health AMR), the successor to the JPIAMR program, have announced the 2nd call in their plan to fund €253 million of AMR research over 10 years. This next call is constructed around the theme of “Transmission.” It opens on 18 Nov 2026 with a budget of EUR 31m
Dear All: As a way to pressure test your candidate compounds, PACE (Pathways to Antimicrobial Clinical Efficacy) and UKHSA (the UK Health Security Agency) have collaborated to release five new contemporary antimicrobial resistance (AMR) strain panels: The five panels contain 145 bacterial strains isolated within the last five years. Available organisms cover the priority Gram-negative
Dear All: CDC have today released an update to their 2019 threat list (i.e., an update to CDC’s priority pathogen list or PPL). Here are the links you need: The webpage for the new report A PowerPoint (.pptx) summarizing all the PPLs to date The PowerPoint as a .pdf.. The AMR.Solutions webpage summarizing all the
Dear All: NIAID/DMID have released their 2027 Omnibus Broad Agency Announcement (BAA) entitled “Development of Medical Interventions for Infectious Diseases.” The key starting point is this link: https://sam.gov/workspace/contract/opp/5f75330f42ee4145990fe6a51a3dc84e/view. Much of this BAA is antiviral but Research Area 2.4 is on point for this newsletter’s audience. The call here is to “improve patient outcomes against serious
Dear All: Oh, no! Hot on the heels of the excellent talk at GAMRIC by Karen Bush in which the importance of relebactam as one of our most advanced beta-lactamase inhibitors was highlighted, we have this: Screenshot from drugs.com Yes, that’s right, Merck have notified the US FDA that imipenem-cilastatin-relebactam (RECARBIO) is being withdrawn from
Dear All: We need to make Pull incentives work! On this theme, our first topic for today is an opportunity for organizations to sign a letter of support for PASTEUR. This letter is co-led by the AMR Action Fund, BIO, Cystic Fibrosis Foundation, Infectious Diseases Society of America and Partnership to Fight Infectious Diseases. Here
Dear All: CARB-X have just announced their 2nd 2026 call for applications. There are 4 thematic areas for your proposals: Direct-acting therapeutics for infections caused by Gram-negative bacteria “Proposals must target the development of agents for the treatment of Gram-negative priority pathogens” (see our Bugs & Drugs page). Novel Chemistry for AMR Challenge: target-based therapeutics
Dear All: Significantly strengthening our database documenting the human cost of AMR, we now have an impressive survey of mortality associated with severe infections in 19 Asian countries during the period Sep 2022 to Feb 2025. Here are the links you need: (the primary paper): Mo Y, Hao X, Ding Y et al. Severe health-care-associated
Note: I’ve been away on holiday (see the newsletter’s postscript) and so there are multiple new items in both the meetings calendar and the list of funding opportunities: TB! PACCARB! Funding for antifungals! Funding for R&D in India! Look closely! Dear All: The AMR Multi-Stakeholder Partnership Platform (AMR MSPP) collaborated with the Milken Institute on
Dear All: An important and instructive analysis of optimal global antibiotic usage targets has just been published in Lancet Public Health. To follow the plot, here are the links you need: The new paper: Cook et al.: “Benchmarking AWaRe: estimating optimal levels of AWaRe antibiotic use in 186 countries, territories and areas based on clinical